Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall ...

Germline mutations of the gene encoding human fibroblast growth factor receptor 3 (FGFR3) have been shown to be responsible for several related autosomal dominant forms of syndromic ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

The advent of next-generation antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has transformed our understanding of human epidermal growth factor receptor 2 (HER2) ...

Mean age for patients with CKD was 72 years, 36% were men, 82% were Black and the mean eGFR was 35 mL/min/1.73 m 2. In the non-CKD group, mean age was 34 years, 51% were men, 36% were Black and ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Pathophysiology of HER2-positive Breast Cancer Human epidermal growth factor receptor 2 (HER2) is a membrane-spanning receptor that belongs to the family of epidermal growth factor receptor ...

Title: Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs. fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC): results of the ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive ...